HOME >> MEDICINE >> NEWS
NIAID launches program to improve medical tools against emerging infectious diseases

The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), has awarded 14 contracts totaling more than $73 million to fund the Large-Scale Antibody and T Cell Epitope Discovery Program, an initiative aimed at quickly identifying the regions of selected infectious agents that elicit immune reactions. The study of these regions, known as epitopes, promises to uncover targets for new and improved vaccines, therapies and diagnostic tools against potential bioterror agents as well as emerging/re-emerging infectious diseases such as West Nile virus and influenza. NIAID will make information on each newly identified epitope freely available to scientists through a searchable online database currently under development.

"Elucidating the basic mechanisms of immune function is a major focus of our biodefense research agenda," says Anthony S. Fauci, M.D., director of NIAID. "The information generated by this program will deepen our understanding of how components of the immune system defend against certain infectious agents, enabling researchers to design new and improved medical countermeasures."

"Researchers have been conducting epitope discovery for many years, but generally on a small scale," says Daniel Rotrosen, M.D., director of NIAID's Division of Allergy, Immunology and Transplantation. "This initiative, however, will yield new knowledge about antigenic epitopes from a wide variety of microbes, including agents that might be used in a bioterrorist attack."

Epitopes are recognized by the body's B and T cells, white blood cells that detect an invading pathogen. Each B and T cell is specific for a particular antigen, meaning that each can only bind to a certain foreign molecular structure. This "specificity" is determined by the receptors on the surface of each cell.

Both B- and T-cell specificity as well as the diverse functions of these cells determine the effectiveness of an immu
'"/>

Contact: Paul Williams
pw81y@nih.gov
301-402-1663
NIH/National Institute of Allergy and Infectious Diseases
1-Nov-2004


Page: 1 2 3

Related medicine news :

1. NIAID initiates trial of experimental avian flu vaccine
2. NIAID seeks applicants to lead clinical trials units for revamped HIV/AIDS networks
3. NIAID begins enrolling volunteers for novel HIV vaccine study
4. NIAID-sponsored clinical trial aims to boost flu vaccine supply
5. NIAID seeks applicants to lead revamped HIV/AIDS clinical trials networks
6. NIAID launches influenza genome sequencing project
7. NIAID forms network to tackle potentially fatal reaction to smallpox vaccine
8. NIAID rotavirus vaccine licensed for commercialization
9. Second NIAID SARS vaccine candidate helps mice fend off SARS
10. NIAID vaccine protects against SARS virus infection in mice
11. NIAID Ebola vaccine enters human trial

Post Your Comments:
(Date:4/1/2015)... 2015 San Francisco based sustainable medical ... medical charity, Operation Smile, have launched a ... Campaign Details: RxOrganics is generously donating 5% of ... Operation Smile throughout 2015. RxOrganics has committed to an ... that every order placed online through the Rxmedical shop ...
(Date:4/1/2015)... April 01, 2015 Results are in ... , which featured 11 new homes from across the ... that best utilized innovative building techniques and new technology ... Steven Winter Associates, Inc. (SWA) provided sustainability consulting services ... year’s challenge, including the first- and third-place winners. , ...
(Date:4/1/2015)... 01, 2015 Poisonous plants (poison ivy, ... change in recent years, increasing significantly in number and ... if exposed to poison plants (according to the American ... prepare for summer adventures in nature, they should be ... reaction is greater than ever. This year, Ivarest adds ...
(Date:3/31/2015)... Bon Secours New York Health System ... Nursing Care Center family last week. The Sisters formerly ... Yonkers which is scheduled to close later this year. ... the Sisters of Charity of New York, the decision ... place their Sisters at Schervier Nursing Care Center followed ...
(Date:3/31/2015)... As the demand for optimized mobile content ... a mobile-friendly website online sometime during the month of ... continued commitment to bring the best and most accurate ... the same great fitness information at http://www.chunkfitness.com ... to read while browsing on a mobile device. , ...
Breaking Medicine News(10 mins):Health News:RxOrganics Forges Unique Partnership to Bring More Smiles to Underserved Global Heath Communities 2Health News:Steven Winter Associates’ Projects Receive Top Honors in CT Zero Energy Challenge 2Health News:Steven Winter Associates’ Projects Receive Top Honors in CT Zero Energy Challenge 3Health News:Steven Winter Associates’ Projects Receive Top Honors in CT Zero Energy Challenge 4Health News:New Ivarest Poison Ivy Itch Spray Provides All-Day Comfort 2Health News:Bon Secours New York Health System Welcomes Retired Sisters of Charity to the Family 2
(Date:3/31/2015)... 2015 Neurocrine Biosciences, Inc. (Nasdaq: NBIX ... exclusive collaboration and licensing agreement for the development and ... Japan and other select Asian markets with ... to initially develop NBI-98854 in Japan ... tardive dyskinesia. Neurocrine retains full commercial rights to NBI-98854 ...
(Date:3/31/2015)... UHC has released the findings of a ... based on cost and quality outcomes to uncover several ... study examined utilization of PPIs—which can account for 30% ... 10 academic medical centers, focusing on procedures utilizing orthopedic ... The study, begun in 2013, integrated the ...
(Date:3/31/2015)... N.Y., March 31, 2015 Uroplasty, Inc. (NASDAQ: ... the completion of their merger. The merger was ... the all-stock combination creates a new medical device ... 1, 2015, Cogentix Medical, Inc. will trade on ... will have its U.S. headquarters in ...
Breaking Medicine Technology:Neurocrine Biosciences and Mitsubishi Tanabe Pharma Announce Agreement to Develop and Commercialize VMAT2 Inhibitor NBI-98854 for Movement Disorders in Japan and Other Select Asian Markets 2Neurocrine Biosciences and Mitsubishi Tanabe Pharma Announce Agreement to Develop and Commercialize VMAT2 Inhibitor NBI-98854 for Movement Disorders in Japan and Other Select Asian Markets 3Neurocrine Biosciences and Mitsubishi Tanabe Pharma Announce Agreement to Develop and Commercialize VMAT2 Inhibitor NBI-98854 for Movement Disorders in Japan and Other Select Asian Markets 4UHC Study: Variations in Use of Physician Preference Items Affect Patient Outcomes and Costs 2UHC Study: Variations in Use of Physician Preference Items Affect Patient Outcomes and Costs 3Uroplasty and Vision-Sciences Complete Merger 2Uroplasty and Vision-Sciences Complete Merger 3Uroplasty and Vision-Sciences Complete Merger 4
Cached News: